2023 Annual Meeting | H227 - Alzheimer's Network for Diagnostics and Therapy (ALZ-NET): Using Real World Evidence to Define the Future of Alzheimer's Treatment and Care (Research Hub)

Date Tuesday 04/25/23

Time 01:00 PM - 01:45 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Hubs (Research)

Director(s) Heather M. Snyder, PhD

Topic(s) Aging and Dementia, Education, Research, and Methodology

Learning Objectives The Alzheimer's Association, American College of Radiology, American Society of Neuroradiology, the Department of Biostatistics, Brown University School of Public Health and the Critical Path Institute, along with international clinical, research and imaging experts, have launched the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET).Networks of dementia clinics and imaging facilities are the foundation of ALZ-NET and will expand over time to include a variety of clinical practices. Patients about to start or already receiving treatment with a novel FDA-approved AD therapy will be eligible to enroll in ALZNET. ALZ-NET is structured to collect a data set that aligns with patient care, agnostic of therapy and care setting, including, baseline demographic, medical, neurologic, genetic and biomarker data. Join us to learn more about ALZ-NET.

CME Available 0.00 CME credit

Core Competencies Patient Care & Procedural Skills, Systems-based Practice

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic

Event Timeline
01:00 PM - 01:45 PM EST	Speaker	Alzheimer's Network for Diagnostics and Therapy (ALZ-NET) - Using Real World Evidence to Define the Future of Alzheimer's Treatment and Care Heather M. Snyder, PhD, Michael S. Rafii, MD, PhD

Faculty Disclosures
Heather M. Snyder, PhD	Dr. Snyder has received personal compensation for serving as an employee of Alzheimer's Association. An immediate family member of Dr. Snyder has received personal compensation for serving as an employee of Abbott . An immediate family member of Dr. Snyder has stock in Medtronic. The institution of Dr. Snyder has received research support from National Institute on Aging.
Michael S. Rafii, MD, PhD	Dr. Rafii has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. Dr. Rafii has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Keystone Bio. Dr. Rafii has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alzheon.